CommercialCoverageMedium impact
Injectable Fillers for Dermal and Laryngeal Conditions 7.01.119
Excellus BlueCross BlueShield·Dermatology, ENT (Ear, Nose & Throat), Plastic Surgery +1 more·Miscellaneous
Effective date
Sep 18, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has established a new medical policy defining coverage criteria for injectable fillers. The policy covers specific dermal fillers (Sculptra, Radiesse) for HIV-related facial lipodystrophy and laryngeal injections (calcium hydroxylapatite, autologous fat) for vocal cord paralysis and type 1 laryngeal cleft, while declaring all other injectable filler uses as not medically necessary.
Action Required
Before September 18, 2025: Billing team must update prior authorization requirements for injectable filler procedures to ensure they meet the specific medical necessity criteria outlined in policy 7.01.119. Verify that dermal filler claims are limited to FDA-approved products for HIV facial lipodystrophy and laryngeal injections are for vocal cord paralysis/insufficiency or failed conservative therapy for type 1 laryngeal cleft. All other injectable filler requests will be denied as not medically necessary.